Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
34.15
+0.65 (1.94%)
At close: Feb 11, 2026

TPEX:7427 Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
1.781.694.850.540.63-
Revenue Growth (YoY)
189.59%-65.26%798.15%-14.29%--
Cost of Revenue
0.720.670.040.080.35-
Gross Profit
1.071.024.810.460.28-
Selling, General & Admin
23.4428.5717.519.3717.710.42
Research & Development
69.0985.0953.1349.8919.1119.47
Operating Expenses
92.53113.6670.6369.2636.829.89
Operating Income
-91.46-112.65-65.82-68.79-36.52-29.89
Interest Expense
-0.11-0.13-0.09---0.02
Interest & Investment Income
8.527.795.330.940.520.03
Currency Exchange Gain (Loss)
0.060.06-0.540.330.13-0
Other Non Operating Income (Expenses)
0.01000.390.020.44
EBT Excluding Unusual Items
-82.99-104.92-61.12-67.13-35.86-29.44
Gain (Loss) on Sale of Assets
--0.12---
Asset Writedown
------2.57
Other Unusual Items
-4.76----0.74
Pretax Income
-87.75-104.92-61-67.13-35.86-31.27
Net Income
-87.75-104.92-61-67.13-35.86-31.27
Net Income to Common
-87.75-104.92-61-67.13-35.86-31.27
Shares Outstanding (Basic)
434136242116
Shares Outstanding (Diluted)
434136242116
Shares Change (YoY)
12.53%13.60%50.23%14.54%33.09%16.83%
EPS (Basic)
-2.02-2.55-1.68-2.78-1.70-1.97
EPS (Diluted)
-2.03-2.55-1.68-2.78-1.70-1.97
Free Cash Flow
-79.66-78.96-57.92-77.21-33.96-41.9
Free Cash Flow Per Share
-1.83-1.92-1.60-3.20-1.61-2.65
Gross Margin
59.80%60.24%99.11%85.93%44.92%-
Operating Margin
-5135.32%-6685.28%-1357.11%-12739.07%-5796.98%-
Profit Margin
-4927.12%-6226.94%-1257.67%-12431.85%-5691.59%-
Free Cash Flow Margin
-4472.71%-4685.82%-1194.21%-14298.70%-5389.68%-
EBITDA
-86.67-108.62-63.22-67.03-35.08-28.9
D&A For EBITDA
4.84.032.61.761.440.98
EBIT
-91.46-112.65-65.82-68.79-36.52-29.89
Source: S&P Global Market Intelligence. Standard template. Financial Sources.